Cytomegalovirus Infection Clinical Trial
Official title:
Adoptive Transfer of Cord Blood T Cells To Prevent and Treat CMV and Adenovirus Infections After Transplantation
With this study, we want to see if we can use a kind of white blood cell called T cells to prevent or treat AdV and CMV infection. We will grow these T cells from the cord blood before the patients transplant. These cells have been trained to attack adenovirus/CMV-infected cells and are called Adenoviral/CMV-specific cytotoxic (killer) T-cells or "AdV/CMV-CTL." We would plan to give the patient one dose of AdV/CMV-CTL any time from 30 days after their transplant. We have used T cells made in this way from the blood of donors to prevent infections in patients who are getting a bone marrow or blood stem cell transplant but this will be the first time we make them from cord blood.
We plan to grow T cells from the cord blood in the laboratory in a special way, to see if
they can help prevent or treat infections in transplant patients with these viruses. This
therapy with specially trained T cells (called CTLs) has had activity against these viruses
when the cells are made from donor blood and given to patients receiving bone marrow or
blood stem cell transplants. We want to find out if we can use CTLs that we will make from
cord blood to prevent or treat viral infections when the patient's immunity is weak after
receiving the cord blood transplant. These cells are called "CMV/AdV specific CTLs" because
they can attack those two viruses.
The doctor will already have found a cord blood unit that is suitable for the patient's
transplant. If the patient agrees to this study we will take 5-10 ml (1-2 teaspoons) from
this cord blood unit before the transplant. We will only take as much cord blood as is
available in a specially frozen small fraction of the cord blood unit.
We will use this cord blood to grow T cells in the lab. From this blood we will first grow
special type of cells called dendritic cells and we will put a specially produced human
virus (adenovirus) that carries the CMVpp65 gene into these dendritic cells. The dendritic
cells will be irradiated so they cannot grow and then used to stimulate the T cells. This
stimulation will train the T cells to kill cells with CMV and adenovirus on their surface.
We will then grow large numbers of these AdV/CMV-specific CTLs by more stimulation with EBV
infected B cells (which we will make from the cord blood by infecting them with EBV in the
laboratory). We will also put the special virus into these B cells so that they too have
AdV/CMV. Again, these B cells will be treated with radiation so they cannot grow. Once we
have made enough T cells we will test them to make sure they kill cells infected with
Adenovirus and CMV. To make sure that these cells won't attack the patient's own healthy
tissues, we test these cells against some of the blood cells that we will grow in the
laboratory. These will be used to check to see if the AdV/CMV CTL can attack them.
Alternatively, we may take blood from a first degree relative or take a small piece of skin
from the patient to grow skin cells, which can also to be used to check if AdV/CMV CTL can
attack them. The skin biopsy can be done at the same time as another procedure such as a
bone marrow biopsy.
The cord donor's AdV/CMV CTL cells will be thawed and injected into the IV line over a
period of up to 10 minutes.Patients may be premedicated with Benadryl and Tylenol. If the
patient agrees and if he/she is well enough, one dose of CTL will be given on or after day
30 following transplant. If the patient does not have AdV/CMV infection we will not give
antiviral medications to them during this study but we will monitor the patient closely to
check for AdV/CMV infection. If the patient does have AdV/CMV infection before CTL infusion
they may also be treated with antiviral medications during this study. We will monitor the
patients closely for AdV/CMV infection by collecting blood and possibly urine and stool and
testing them for AdV/CMV.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
Completed |
NCT00370006 -
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
Completed |
NCT00386412 -
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
|
Phase 2 | |
Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03910478 -
Dried Blood Spot Testing of CMV Detection in HCT Recipients
|
N/A | |
Completed |
NCT01354301 -
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
|
Phase 4 | |
Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 | |
Completed |
NCT00194155 -
Cytomegalovirus (CMV) Infection in Pregnancy
|
N/A |